home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Change Control Best Practices - Avoiding Unintended Consequences of Changes

 
  July 24, 2020  
     
 
Compliance online, Online Event
July 27-28,2020


One of the top 10 FDA 483 and Warning Letter citations is for inadequate change control. Change control receives detailed scrutiny during FDA inspections, and FDA reviews change control documentation to determine that changes did not adversely impact products, processes, equipment, facilities, etc. A single inadequate change may lead to significant negative events, including release of sub-standard product or product recall. A pattern of inadequate changes may require costly and time-consuming system remediation efforts.

It is therefore critically important to assure that changes are properly described, justified, assessed for risk, implemented, and documented. Changes must also be prospectively reviewed by appropriate subject matter experts. Furthermore, certain major changes (e.g. manufacturing, specifications) may require regulatory filings and/or prior regulatory approval.

This seminar will help all personnel involved in proposing, assessing, and implementing changes to understand and successfully apply Change Control best practices. Key focus will be placed on change proposals, justification / risk assessment and change execution / implementation. The importance of proper planning, critical thinking skills, and co-ordination of all change activities will also be discussed. Techniques for assuring robust Change Control programs in light of COVID-19 restrictions will also be discussed.

This is a practical how-to course, designed to provide participants with skills they can immediately apply to change controls within their own organizations. Case studies will allow participants to practice skill sets in cooperation with the instructor.

Learning Objectives:

Upon completing this course, participants should be able to:

  • Understand the purpose of change control
  • Understand regulatory requirements and FDA expectations for change control
  • Identify what types of changes are /are not subject to change control
  • Properly describe changes
  • Properly justify changes
  • Develop a comprehensive Change Execution Plan
  • Conduct a proper change Risk Assessment
  • Ensure proper execution of changes
  • Ensure proper implementation of changes
  • Develop a complete Change Control documentation package
  • Utilize critical thinking skills throughout the change control process
  • Avoid pitfalls during the change control process

Who will Benefit:

This course is designed for people tasked with:

  • Authoring change proposals
  • Assessing / approving change proposals
  • Executing / implementing changes

The following personnel will benefit from the course:

  • Change proposal authors
  • Reviewers / approvers of change controls
  • Change control system owners
  • Production staff / management
  • Engineering staff / management
  • Validation staff /management
  • QC staff / management
  • Regulatory Affairs staff / management
  • QA staff / management

This course is designed from a pharmaceutical manufacturing perspective; however, since the main focus is on techniques and practices, the course material may be equally applied to biologics and medical device environments. Please note that this seminar focuses on changes to equipment, facilities, materials/components, test methods, suppliers, specifications, etc. Document Change Control is discussed as a supporting element; however, it is not the main focus.

 
 
Organized by: ComplianceOnline
Invited Speakers:
Andrew Campbell

Andrew Campbell
Pharmaceutical Consultant - Quality & Compliance

Andrew Campbell has 25 years of pharmaceutical quality assurance and quality systems experience in both industry and consulting roles. Mr. Campbell has worked in clinical supply and commercial manufacturing environments, and has experience with integrated manufacturing and contract manufacturing business models. He has extensive expertise in the areas of deviation - CAPA, change control, GMP auditing, GMP training, and regulatory inspection preparation and management.

Working with large and small companies, Mr. Campbell has successfully developed, remediated and implemented key quality systems. He is a skilled GMP auditor, and has audited multiple API, drug product, packaging, testing, and distribution facilities. He is an experienced GMP trainer, and has developed customized and interactive training presentations for many companies. He has also provided FDA inspection support for several clients, including readiness training, on-site assistance during inspections, and authoring written responses to inspectional observations. Prior to becoming a consultant in 2007, Mr. Campbell worked for Ligand Pharmaceuticals as director of quality systems.

 
Deadline for Abstracts: 2020-07-24
 
Registration: For registration visit:https://www.complianceonline.com/fda-change-control-expectations-best-practices-seminar-training-80244SEM-prdsm?channel=hum-molgen
E-mail: referral@complianceonline.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.